Serum matrix metalloproteinase‐9 is elevated in men with a history of myocardial infarction

References

• Johnson JL, Jackson CL, Angelini GD, George SJ. Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 1998; 18: 1707–15.
   PubMed Web of Science ®Google Scholar
• Galis ZS, Asanuma K, Godin D, Meng X. N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage derived foam cells: new target for antioxidant therapy? Circulation 1998; 97: 2445–53.
   PubMed Web of Science ®Google Scholar
• Schonbeck U, Mach F, Sukhova GK, Murphy C, Bonnefoy JY, Fabunmi RP, Libby P. Regulation of matrix metalloproteinase expression in human vascular muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ Res 1997; 81: 448 — 54.
   Google Scholar
• Willerson JT. Systemic and local inflammation in patients with unstable atherosclerotic plaques. Prog Cardiovasc Dis 2002; 44: 469–78.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973–9.
   Google Scholar
• Muscari A, Bozzoli C, Puddu GM, Sangiorgi Z, Dormi A, Rovinetti C, Descovich GC, Puddu P. Association of serum C3 levels with the risk of myocardial infarction. Am J Med 1995; 98: 357–64.
   PubMed Web of Science ®Google Scholar
• Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493–503.
   PubMed Web of Science ®Google Scholar
• Kalela A, P6nni6 M, Koivu TA, flöyhtyä M, Huhtala H, Sillanaukee P, Nikkari ST. Associa-tion of serum sialic acid and MMP-9 with lipids and inflammatory markers. Eur J Clin Invest 2000; 30: 99–104.
   Google Scholar
• Lehtimaki T, Lehtinen S, Solakivi T, Nikkild M, Jaakkola 0, Jokela H, Yld-Herttuala S, Luoma JK, Koivula T, Nikkari T. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol 1999; 19: 23–7.
   Google Scholar
• Erkkild AT, Narvanen 0, Lehto S, Uusitupa MI, Yld-Herttuala S. Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2000; 20: 204–9.
   Google Scholar
• Maggi E, Finardi G, Poli M, Bollati P, Filipponi M, Stefano PL, Paolini G, Grossi A, Clot P, Albano E, Bellomo G. Specificity of auto-antibodies against oxidized LDL as an additional marker for atherosclerotic risk. Coron Artery Dis 1993; 4: 1119–22.
   Google Scholar
• Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868–74.
   PubMed Web of Science ®Google Scholar
• Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A. HDL and atherosclerosis: beyond reverse cholesterol trans-port. Atherosclerosis 2002; 161: 1–16.
   PubMed Web of Science ®Google Scholar
• Weber KT, Sun Y, Katwa LC. Wound healing following myocardial infarction. Clin Cardiol 1996; 19: 447–55.
   Google Scholar
• Puska P, Tuomilehto J, Nissinen A, Vartiainen E. The North Karelia Project. 20 year results and experiences. Helsinki: Helsinki University Printing House; 1995.
   Google Scholar
• Soini Y, Hurskainen T, flöyhtyä M, Oikarinen A, Autio-Harmainen H. 72 kD and 92 kD type IV collagenase, type IV collagen, and laminin mRNAs in breast cancer: a study by in situ hybridization. J Histochem Cytochem 1994; 42: 945 — 51.
   Google Scholar
• Uusitupa MI, Niskanen L, Luoma J, Vilja P, Mercuri M, Rauramaa R, Yld-Herttuala S. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996; 16: 1236–42.
   Google Scholar
• Kalela A, Koivu TA, Sisto T, Kanervisto J, flöyhtyä M, Sillanaukee P, Lehtimaki T, Nikkari ST. Serum matrix metalloproteinase-9 concentra-tion in angiographically assessed coronary artery disease. Scand J Clin Lab Invest 2002; 62: 337–42.
   Google Scholar
• Nguyen M, Arkell J, Jackson CJ. Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol 2001; 33: 960–70.
   PubMed Web of Science ®Google Scholar
• Hrabec E, Strek M, Nowak D, Hrabec Z. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Respir Med 2001; 95: 1–4.
   PubMed Web of Science ®Google Scholar
• Endo K, Maehara Y, Baba H, Yamamoto M, Tomisaki S, Watanabe A, Kakeji Y, Sugimachi K. Elevated levels of serum and plasma metallopro-teinases in patients with gastric cancer. Anticancer Res 1997; 17: 2253–8.
   PubMed Web of Science ®Google Scholar
• Kelly EA, Busse WW, Jarjour NN. Increased matrix metalloproteinase-9 in the airway after allergen challenge. Am J Respir Crit Care Med 2000; 162: 1157–61.
   Google Scholar
• Gruber BL, Sorbi D, French DL, Marchese MJ, Nuovo GJ, Kew RR, Arbeit LA. Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful labora-tory marker. Clin Immunol Immunopathol 1996; 78: 161–71.
   Google Scholar
• Pugin J, Widmer MC, Kossodo S, Liang CM, Preas HL II, Suffredini AF. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am J Respir Cell Mol Biol 1999; 20: 458–64.
   PubMedGoogle Scholar
• Burke AP, Tracy RP, Kolodgie F, Malcom GT, Zieske A, Kutys R, Pestaner J, Smialek J, Virmani R. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation 2002; 105: 2019–23.
   Google Scholar
• Blackburn R, Giral P, Bruckert E, Andre JM, Gonbert S, Bernard M, Chapman MJ, Turpin G. Elevated C-reactive protein constitutes an inde-pendent predictor of advanced carotid plaques in dyslipidemic subjects. Arterioscler Thromb Vasc Biol 2001; 21: 1962–8.
   PubMed Web of Science ®Google Scholar
• Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000; 102: 100–6.
   Google Scholar
• Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, Summaria F, Ginnetti F, Fadda G, Maseri A. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999; 99: 855–60.
   PubMed Web of Science ®Google Scholar
• Ablij HC, Meinders AE. C-reactive protein: history and revival. Eur J Intern Med 2002; 13: 412— 22.
   Google Scholar
• Muscari A, Massarelli G, Bastagli L, Poggiopollini G, Tomassetti V, Volta U, Puddu GM, Puddu P. Relationship between serum C3 levels and tradi-tional risk factors for myocardial infarction. Acta Cardiol 1998; 53: 345–54.
   PubMedGoogle Scholar
• Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, Bernini F. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998; 18: 1671–78.
   PubMed Web of Science ®Google Scholar
• Kalela A, Laaksonen R, Lehtimäki T, Koivu TA, Höyhtyä M, Janatuinen T, Pöllänen P, Vesalainen R, Saikku P, Knuuti J, Nikkari ST. Effect of pravastatin in mildly hypercholesterolemic young men on serum matrix metalloproteinases. Am J Cardiol 2001; 88: 173-5, A6.
   Google Scholar
• Reinhardt D, Sigusch HH, Hene J, Tyagi SC, Körfer R, Figulla HR. Cardiac remodelling in end stage heart failure: upregulation of matrix metal-loproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart 2002; 88: 525— 30.
   Google Scholar
• Yld-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Wiztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994; 14: 32–40.
   Google Scholar
• Schumacher M, Eber B, Tatzber F, Kaufmann P, Halwachs G, Fruhwald FM, Zweiker R, Esterbauer H, Klein W. Transient reduction of autoantibodies against oxidized LDL in patients with acute myocardial infarction. Free Radic Biol Med 1995; 18: 1087–91.
   Google Scholar
• van de Vijver LP, Steyger R, van Poppel G, Boer JM, Kruijssen DA, Seidell JC, Princen HM. Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis 1996; 122: 245— 53.
   PubMedGoogle Scholar
• Hulthe J, Wikstrand J, Lidell A, Wendelhag I, Hansson GK, Wiklund 0. Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1998; 18: 1203–11.
   Google Scholar
• Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB. C-reactive protein, a sensitive marker of inflam-mation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from MONICA (Monitoring trends and determinants in cardiovascular disease) Augsburg cohort study, 1984 to 1992. Circulation 1999; 99: 237–42.
   PubMed Web of Science ®Google Scholar